Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.43 |
| ▸ | JAK2 | O60674 | 14/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27379517 | 0.94 | BTK (0.41) | BTKJAK2KDM4EHTTTNKS | |
| SCHEMBL29326746 | 0.90 | PTGES (0.38) | BTKJAK2KDM4EHTTTNKS | |
| SCHEMBL29326720 | 0.88 | PTGES (0.39) | BTKJAK2KDM4EHTTTNKS2 | |
| SCHEMBL29326749 | 0.86 | PTGES (0.41) | BTKJAK2KDM4EHTT | |
| SCHEMBL29326689 | 0.86 | PTGES (0.48) | KDM4EHTT | |
| SCHEMBL29326721 | 0.85 | PKM (0.41) | KDM4EHTT | |
| SCHEMBL29326680 | 0.85 | BTK (0.39) | BTKJAK2KDM4EHTT | |
| SCHEMBL27379508 | 0.85 | PTGES (0.38) | BTKJAK2KDM4EHTT | |
| SCHEMBL29326735 | 0.85 | KDM4E (0.37) | KDM4EHTTTNKS2 | |
| SCHEMBL29326451 | 0.83 | KDM4E (0.45) | KDM4EHTTTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | BTK 2121/4885JAK2 1797/4885KDM4E 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.